Cardiogenic shock happens when the heart suddenly can’t pump enough blood to meet the body’s needs. This leads to a drop in ...

The outcomes of the SHOCK trial led to a ACC/AHA class 1A recommendation for an early invasive strategy in acute MI complicated by cardiogenic ... ACC/AHA/SCAI 2005 guideline update for ...

Despite substantial advancements in the management of cardiogenic shock, mortality rates remain greater than 40%. Trials have ...

In one of the largest studies of early cardiogenic shock (CS) patients, where blood flow is still functioning to vital organs ...

In one of the largest studies of early cardiogenic shock (CS) patients, where blood flow is still functioning to vital organs, researchers demonstrated that 26% experienced worse outcomes, including ...

A leading interventional cardiologist, he is internationally recognized for his work in hypertrophic cardiomyopathy and cardiogenic shock, and is the lead author of the SCAI SHOCK Classification.

Windtree Therapeutics, Inc. announced that it has received guidance from intellectual property and FDA experts regarding a potential strategy for its drug istaroxime, which targets cardiogenic shock.

The company’s lead asset, Istaroxime, is a first-in-class, dual-acting agent being ... Planned interim analysis of Istaroxime cardiogenic shock SCAI Stage C Phase 2 study for early 2Q25 ...

If istaroxime is granted the new chemical entity designation from FDA, it could provide 7.5 years of U.S. exclusivity and additionally the istaroxime U.S. issued method of use patent protects until ...

In one of the largest studies of early cardiogenic shock (CS) patients ... Society for Cardiovascular Angiography & Interventions (SCAI) 2025 Scientific Sessions. CS is a life-threatening ...